Juno sets IPO terms, presents CAR T data

Juno Therapeutics Inc. (Seattle, Wash.) set terms for its IPO on NASDAQ and now plans to sell 9.25 million shares at $15-$18. At $16.50, Juno would raise $152.6 million and be valued at $1.3 billion. The company filed to raise up to $150 million in November. Morgan Stanley; JPMorgan; Goldman Sachs; and Leerink are underwriters.

On Monday, Juno presented data on its three most advanced programs at the American Society of Hematology (ASH) meeting in San Francisco. All three -- JCAR017, JCAR015 and JCAR014 -- are cancer immunotherapies that use autologous T cells expressing chimeric antigen receptors (CARs) specific to CD19. ...